When transmitting the data, even if the data is de-defined and transmitted, some may consider it to be an invasion of privacy and as a potential source of activity.4,9,33,34 The provision of informed consent of study participants for the future use of biological data or samples is therefore necessary. The informed consent process can use different approaches, for example, in general. B, wide, checklist and study-specific; each format will have an impact on how data or samples will be transmitted in the future.5,35,36 Council for International Medical Organizations and other guidelines generally suggest the use of broad consent for data exchange; This is less specific than consent to any use, but narrower than general consent.5,37-39 However, an empirical study has shown that providing information on data exchange and obtaining broad consent for data exchange, In addition to approval of the primary study, the approval process has become more complex and difficult to understand for study participants, particularly when the study was conducted in rural areas of LMIC.40 A qualitative stakeholder study of a Research Unit based in Thailand showed that clinical trial participants focused primarily on information on the potential benefits and harms of data exchange and the amount of information to be provided on data exchange.28 It is important to have an effective and valid consent process. Broad consent could be valid if, at the time of consent, it was clear what types of individuals or institutions should be shared and how the data would likely be used in great conscience.28,29 In this study, only about half of the researchers felt it was very important to use broad consent to obtain data for exchange. It is postulated that many researchers may generally have applied broad consensus in their studies. This issue needs further consideration. The exchange of data from clinical and public health research has the potential to: 1-3 For these reasons, data exchange has become an essential requirement for biomedical research.1,4 The Council of International Medical Scientists Organizations (CIOMS) states that “researchers, sponsors and research ethics commissions (ICCs) must exchange data for further research where possible.” 5 Joint research is also considered good practice by WHO and other professional organisations6 The second part of the survey invited respondents to assess perceived difficulties or pressures associated with the transmission of their research data: necessary resources (time and money), technical issues (data platforms, data management and interoperable systems), proprietary data issues, issues related to ethical and legal compliance in the transmission of individual data, organizational/institutional policies related to data exchange, organizational/institutional services or assistance in data sharing, quality and integrity of shared data (. B, for example, complete and homogeneous), monitoring the use of “sensitive” or “restricted” data by other researchers, identifying the data set (original work) and recognizing the data repository. Respondents were asked to rate the degree of importance or difficulty of each subject on a Likert scale of 1 to 5, with 1 being the least important/least problematic and 5 indicating the importance/most problematic.